Metopirone

Metyrapone, the active ingredient in Metopirone, is a cortisol synthesis inhibitor presented as a tablet for oral use. It is used in diagnostic testing of adrenal insufficiency and in the treatment of Cushing's syndrome, helping clinicians evaluate adrenal function and manage excess cortisol production.

GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with sourcing from EU‑approved manufacturers.

Metopirone (metyrapone) is employed in endocrine diagnostic testing and in conditions involving excess cortisol production.

Diagnostic testing of adrenal insufficiency: confirms adrenal response by measuring cortisol after a metyrapone challenge. Treatment of Cushing's syndrome: reduces cortisol synthesis in patients with hypercortisolism. Assessment of adrenal function in ACTH stimulation tests: evaluates the adrenal gland’s capacity to produce cortisol.

Metyrapone may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea - Dizziness or light‑headedness - Headache - Fatigue or weakness - Abdominal discomfort

Serious or Rare Side Effects: - Acute adrenal insufficiency - Hypertension or significant blood pressure changes - Severe electrolyte disturbances such as hypokalemia - Allergic reactions including rash or angioedema - Hepatic dysfunction or elevated liver enzymes

When using Metopirone, clinicians should consider several safety measures.

Monitor adrenal function: assess cortisol levels before and during therapy. Adjust dose in hepatic impairment: use caution in patients with liver disease. Avoid abrupt discontinuation: taper under medical supervision. Use with caution in pregnancy: risk unknown, discuss with physician. Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Metyrapone can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Ketoconazole: additive inhibition of cortisol synthesis may cause severe adrenal suppression. - Carbamazepine: enzyme induction may reduce metyrapone efficacy. - Rifampin: increases metabolism, lowering drug levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter steroid metabolism, monitor hormonal levels. - Antihypertensives: cortisol reduction can affect blood pressure, adjust as needed. - Lithium: potential additive effect on adrenal axis, observe patient closely.